Skip to content

A randomized controlled clinical study on the neuroprotection of cerebral infarction convalescent by qi-invigorating blood-activating and resuscitation components

A randomized controlled clinical study on the neuroprotection of cerebral infarction convalescent by qi-invigorating blood-activating and resuscitation components

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068764
Enrollment
Unknown
Registered
2023-02-28
Start date
2023-02-28
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke recovery period

Interventions

Intervention Group:The intervention group (n?=?50) will receive Chinese traditional medicine(borneol, Astragalus and Panax notoginseng) combined with conventional stroke rehabilitation treatment for 4
Control Group:The control group (n?=?50) will receive conventional stroke rehabilitation treatment for 4 weeks

Sponsors

Changde First Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Accorded the western medicine diagnostic criteria of cerebral infarction, the duration is 2-12 weeks; (2) Accorded the TCM diagnostic criteria for ischemic stroke; (3) The National Institutes of Health Stroke Scale (NIHSS) score was 6-22; (4) Men or women aged 18 to 75 years; (5) Voluntary participation and informed consent signed.

Exclusion criteria

Exclusion criteria: (1) Exclude acute cerebral infarction; (2) Transient ischemic attack, lacunar cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage and other cerebrovascular diseases; (3) Cerebral embolism caused by rheumatic heart disease, coronary heart disease and other heart disease combined with atrial fibrillation; stroke patients caused by brain tumors, brain trauma, brain parasitic diseases, blood diseases, etc. ; (4) Diabetic complications and diabetic peripheral neuropathy affect motor function; (5) Liver injury or potential severe liver disease ( ALT or AST > 2 times the normal value ) ; renal dysfunction or damage ( serum creatinine > 2.0 mg/dL or, 177umol/L ) ; or combined with heart, lung, endocrine, blood system and other serious systemic diseases ; (6) Participation in another clinical trial; (7) Unable to follow the medical advice or complete the subsequent treatment or follow-up process; (8) Pregnancy or preparing for pregnancy, lactating women; (9) Allergic to the drug ingredients or high allergy constitution; (10) History of malignancy, and the average life expectancy of less than one year; (11) The researcher considered participants impossible to complete the trial.

Design outcomes

Primary

MeasureTime frame
National Institute of Health stroke scale (NIHSS);Traditional Chinese Medicine Syndrome Scale;

Secondary

MeasureTime frame
Barthel Index rating scale;Minimum Mental State Examination(MMSE);Hamilton Depression Scale(HAMD);Brain tissue damage indicators;Endothelial damage indicators;Inflammatory response indicators;Metabolism related indicators;

Countries

China

Contacts

Public ContactLiuchang

Changde First Hospital of Traditional Chinese Medicine

462783992@qq.com15273688668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026